HBV related Liver disease is a common medical problem in China. An estimated 7.18% of the Chinese (about 93 million) is infected with hepatitis B, and most of the HBV- related hepatitis can developed into liver cirrhosis. Liver transplantation is the only available life saving treatment for patients with end stage liver disease. However, lack of donors, surgical complications, rejection, and high cost are serious problems. stem cells(SCs) possess plasticity and have the potential to differentiate into hepatocyte; Thus, SCs hold great hope for therapeutic applications. Adult bone marrow is the most common source of SCs for clinical applications.Previous study showed that bone marrow derived stem cells (BMSCs) replace hepatocytes in injured liver, and effectively rescue experimental liver failure and contribute to liver regeneration. In this study, the patients with HBV-related liver cirrhosis will undergo administration of human autologous BMSCs via hepatic artery to evaluate the safty and efficacy of human autologous BMSCs treatment for these patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
240
Patients randomized to the intervention arm will be collected for bone marrow stem cells and then infused with these cells via hepatic artery.
Participants will recieve conventional treatment and antivrial treatment.
Xijing Hospital of Digestive Disease
Xi'an, Shaanxi, China
RECRUITINGone year survival rate
Time frame: one year after treatment
MELD score
Time frame: 1week, 4weeks, 3months, 6months, 9 months and 1year after treatment
AFP
Time frame: 1week, 4weeks, 3months, 6months, 9 months and 1year after treatment
renal function
Time frame: 1week, 4weeks, 3months, 6months, 9 months and 1year after treatment
child score
Time frame: 1week, 4weeks, 3months, 6months, 9 months and 1year after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.